Patents by Inventor Paul Parren

Paul Parren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
    Publication number: 20200165349
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: January 31, 2020
    Publication date: May 28, 2020
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 10647763
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: May 12, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 10647764
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: May 12, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 10640554
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: May 5, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • MODULATION OF COMPLEMENT-DEPENDENT CYTOTOXICITY THROUGH MODIFICATIONS OF THE C-TERMINUS OF ANTIBODY HEAVY CHAINS
    Publication number: 20200131253
    Abstract: Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.
    Type: Application
    Filed: April 30, 2019
    Publication date: April 30, 2020
    Inventors: Paul PARREN, Patrick VAN BERKEL, Ewald VAN DEN BREMER
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20200123255
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: September 25, 2019
    Publication date: April 23, 2020
    Inventors: Edward VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Paul PARREN
  • ANTIBODIES AND METHODS OF USE THEREOF IN TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20200123237
    Abstract: The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding.
    Type: Application
    Filed: May 17, 2017
    Publication date: April 23, 2020
    Applicant: Genmab B.V.
    Inventors: Annemarie KUIPERS, Kok van KESSEL, Frank BEURSKENS, Rob de JONG, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN, Jos van STRIJP, Suzan ROOIJAKKERS
  • COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
    Publication number: 20200114000
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
    Type: Application
    Filed: September 12, 2019
    Publication date: April 16, 2020
    Inventors: Jan VAN DE WINKEL, Paul PARREN, Yvo GRAUS, Judith OPRINS, Michel DE WEERS, Martine VAN VUGT, Ole BAADSGAARD, Steen LISBY
  • Heterodimeric antibody Fc-containing proteins and methods for production thereof
    Patent number: 10597464
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: March 24, 2020
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20200087407
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 19, 2020
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Inert format
    Patent number: 10590206
    Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: March 17, 2020
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce Meesters, Joost J. Neijssen, Edward Norbert Van Den Brink, Janine Schuurman, Paul Parren
  • AGONISTIC TNF RECEPTOR BINDING AGENTS
    Publication number: 20200079866
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Application
    Filed: September 25, 2019
    Publication date: March 12, 2020
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • MONOCLONAL ANTIBODIES AGAINST C-MET
    Publication number: 20200079872
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: August 23, 2019
    Publication date: March 12, 2020
    Inventors: Joost J. NEIJSSEN, Bart DE GOEIJ, Edward Norbert VAN DEN BRINK, Aran Frank LABRIJN, Rene HOET, Janine SCHUURMAN, Paul PARREN, Jan VAN DE WINKEL
  • MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137
    Publication number: 20200062853
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Application
    Filed: July 14, 2017
    Publication date: February 27, 2020
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Friederike GIESEKE, Ugur SAHIN
  • PRODUCTION OF HETERODIMERIC PROTEINS
    Publication number: 20200048304
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Application
    Filed: May 30, 2019
    Publication date: February 13, 2020
    Inventors: Michael GRAMER, Amitava KUNDU, Ewald T. J. VAN DEN BREMER, Muriel VAN KAMPEN, Patrick PRIEM, Aran Frank LABRIJN, Joyce I. MEESTERS, Joost J. NEIJSSEN, Janine SCHUURMAN, Paul PARREN, Patrick VAN BERKEL, Werner L. VOS, Arnout F. GERRITSEN
  • Bispecific antibodies against CD3 and CD20
    Patent number: 10544220
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 28, 2020
    Assignee: GENMAB A/S
    Inventors: Patrick Engelberts, Esther Breij, Rik Rademaker, Isil Altintas, David Satijn, Sandra Verploegen, Riemke Van Dijkhuizen Radersma, Edward Van Den Brink, Janine Schuurman, Paul Parren
  • Antibodies binding AXL
    Patent number: 10512688
    Abstract: The present disclosure relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: December 24, 2019
    Assignee: GENMAB A/S
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY
    Publication number: 20190382473
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 19, 2019
    Inventors: Pekka KALLUNKI, Karina FOG, Louise Buur VESTERAGER, Ann-Louise BERGSTRÔM, Florence SOTTY, David SATIJN, Edward VAN DEN BRINK, Paul PARREN, Rik RADEMAKER, Tom VINK, Ibrahim John MALIK, Liliana Christina Pereira MONTEZINHO
  • Antibodies binding AXL
    Patent number: 10500276
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: December 10, 2019
    Assignee: GENMAB A/S
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY
    Publication number: 20190367594
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 5, 2019
    Inventors: Pekka KALLUNKI, Karina FOG, Louise Buur VESTERAGER, Ann-Louise BERGSTRÔM, Florence SOTTY, David SATIJN, Edward VAN DEN BRINK, Paul PARREN, Rik RADEMAKER, Tom VINK, Ibrahim John MALIK, Liliana Christina Pereira MONTEZINHO